Valuation: Tyra Biosciences, Inc.

Market Cap 1.49B 1.29B 1.21B 1.11B 2.08B 143B 2.11B 14.29B 5.58B 71.33B 5.61B 5.48B 238B P/E 2026 *
-9.28x
P/E 2027 * -8.44x
Enterprise Value 1B 869M 815M 743M 1.4B 95.68B 1.42B 9.59B 3.74B 47.9B 3.76B 3.68B 160B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.15%
Yield 2026 *
-
Yield 2027 * -
1 day-1.11%
1 week-7.20%
Current month-21.52%
1 month-23.42%
3 months-30.86%
6 months-10.61%
Current year-4.83%
1 week 24.75
Extreme 24.75
26.8
1 month 24.75
Extreme 24.75
33.72
Current year 24.66
Extreme 24.66
40.65
1 year 9.96
Extreme 9.96
40.65
3 years 6.42
Extreme 6.42
40.65
5 years 4.93
Extreme 4.93
40.65
10 years 4.93
Extreme 4.93
40.65
Manager TitleAgeSince
Chief Operating Officer 51 01/11/2018
Chief Executive Officer 46 01/11/2018
Director of Finance/CFO 69 01/01/2023
Director TitleAgeSince
Chairman 58 01/03/2019
Director/Board Member 46 02/08/2018
Director/Board Member 40 01/01/2020
Date Insider Type Main position Quantity % Market Cap.
12/02/26 Sell

Founder

8,000 0.0150%
12/01/26 Sell

Founder

8,000 0.0150%
19/12/25
Alta Partners Management Co. LP
SellCompany 10,000 0.0187%
Change 5-day change 1-year change 3-year change Capi.($)
-1.11%-7.20%+132.74%+62.57% 1.49B
+2.07%+13.76%+65.44%+106.53% 71.56B
-1.96%-3.12%+32.84%+61.76% 54.43B
-4.50%-4.69%+2.82%+463.22% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
-0.67%+1.02%-18.32%-13.84% 23.14B
+0.32%+1.65%+39.32%-19.84% 18.65B
+0.35%+12.02%+257.19%+466.50% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+0.46%-3.05%+31.49%+135.18% 12.54B
Average -0.73%+2.93%+61.00%+188.12% 26.8B
Weighted average by Cap. -0.48%+3.57%+51.04%+162.40%

Financials

2026 *2027 *
Net sales - -
Net income -178M -154M -144M -132M -248M -16.96B -252M -1.7B -664M -8.49B -667M -653M -28.32B -212M -183M -172M -157M -295M -20.2B -300M -2.03B -791M -10.11B -795M -777M -33.73B
Net Debt -491M -425M -399M -363M -684M -46.82B -695M -4.69B -1.83B -23.44B -1.84B -1.8B -78.19B -323M -280M -262M -239M -450M -30.82B -457M -3.09B -1.21B -15.43B -1.21B -1.19B -51.46B
Logo Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).
Employees
87
Date Price Change Volume
13/08/26 $25.02 -1.11% 528,378
12/08/26 $25.30 +0.48% 478,347
11/08/26 $25.18 -4.08% 730,128
10/08/26 $26.25 -0.98% 439,504
07/08/26 $26.51 -1.67% 820,623
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
25.02USD
Average target price
50.82USD
Spread / Average Target
+103.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TYRA Stock